XML 86 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1

SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Revenues Disaggregated by Timing of Revenue Recognition (Details) - USD ($)	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue	$ 11,250,000	$ 7,497,000	$ 26,107,000	$ 40,744,000	$ 6,216,000	$ 7,269,000	$ 33,604,000	$ 13,485,000	$ 44,854,000	$ 54,229,000	$ 59,570,000	$ 64,448,000
Related Party | Mundipharma Medical Company | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											16,421,000	14,256,000
Related Party | Mundipharma Medical Company | License of Intellectual Property - upon transfer of license | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue												0
Related Party | Mundipharma Medical Company | License of Intellectual Property - upon milestones achieved | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											3,252,000	3,252,000
Related Party | Mundipharma Medical Company | Clinical Drug Supply | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											26,000	484,000
Related Party | Mundipharma Medical Company | Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											0	0
Related Party | Mundipharma Medical Company | Royalties | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											0
Related Party | Mundipharma Medical Company | Research and Development Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											12,303,000	9,595,000
Related Party | Mundipharma Medical Company | Clinical Supply Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											840,000	925,000
Related Party | Janssen Pharmaceuticals, Inc. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											23,283,000	23,496,000
Related Party | Janssen Pharmaceuticals, Inc. | License of Intellectual Property - upon transfer of license | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue												0
Related Party | Janssen Pharmaceuticals, Inc. | License of Intellectual Property - upon milestones achieved | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											2,347,000	976,000
Related Party | Janssen Pharmaceuticals, Inc. | Clinical Drug Supply | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											0	0
Related Party | Janssen Pharmaceuticals, Inc. | Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											0	0
Related Party | Janssen Pharmaceuticals, Inc. | Royalties | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											0
Related Party | Janssen Pharmaceuticals, Inc. | Research and Development Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											19,011,000	18,814,000
Related Party | Janssen Pharmaceuticals, Inc. | Clinical Supply Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											1,925,000	3,706,000
Related Party | Melinta Therapeutics Inc | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											19,866,000	26,696,000
Related Party | Melinta Therapeutics Inc | License of Intellectual Property - upon transfer of license | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue												25,885,000
Related Party | Melinta Therapeutics Inc | License of Intellectual Property - upon milestones achieved | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											17,257,000	0
Related Party | Melinta Therapeutics Inc | Clinical Drug Supply | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											0	0
Related Party | Melinta Therapeutics Inc | Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											200,000	0
Related Party | Melinta Therapeutics Inc | Royalties | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											168,000
Related Party | Melinta Therapeutics Inc | Research and Development Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											2,441,000	811,000
Related Party | Melinta Therapeutics Inc | Clinical Supply Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											$ 0	$ 0

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-SubTopic 10
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479428/808-10-45-3

+ Details

Name:	us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=cdtx_ClinicalDrugSupplyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=cdtx_ResearchAndDevelopmentServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=cdtx_ClinicalSupplyServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: